HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
October 23, 2015
-
REGULATORY New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
October 22, 2015
-
BUSINESS Development of Osteoporosis Drugs in Homestretch, Odanacatib’s US Filing Expected by Year-End
October 21, 2015
-
BUSINESS Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
-
REGULATORY Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
-
BUSINESS Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
-
BUSINESS Eisai, Ajinomoto Link Arms to Create Leading Specialty Pharma for GI Disease
October 16, 2015
-
REGULATORY Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
-
ORGANIZATION AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
-
REGULATORY MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
-
REGULATORY TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
-
REGULATORY Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
-
REGULATORY 8 Year Biologic Data Protection in TPP Won’t Affect Japan: MHLW Official
October 7, 2015
-
REGULATORY MHLW Looks to Establish Panel to Draft Guidelines for English-Language Inserts
October 6, 2015
-
BUSINESS Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
-
ORGANIZATION Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
-
ORGANIZATION New 3 Price-Band Rule Will Boost Predictability, Foster Healthy Competition: JGA Officials
October 2, 2015
-
REGULATORY Chuikyo Debate Heats Up on Number of Generic Brands, Makers; JGA Floats New 3 Price-Band Rule
October 1, 2015
-
ORGANIZATION “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
-
ORGANIZATION Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
